Amyloid Imaging AUC Guidelines
Clinical scenario | Score |
---|---|
Appropriate use (scores of 7–9) | |
5. Patients with MCI or dementia who are <65 y old and in whom AD pathology is suspected | 9 |
6. Patients with MCI or dementia syndrome that is often consistent with AD pathology (amnestic presentation), with onset at ≥65 y | 8 |
7. Patients with MCI or dementia syndrome that could be consistent with AD pathology but has atypical features (e.g., nonamnestic clinical presentation, rapid or slow progression, etiologically mixed presentation) | 8 |
11. Patients with MCI or dementia with equivocal or inconclusive results on recent cerebrospinal fluid biomarkers | 8 |
12. Patients with mild cognitive impairment due to clinically suspected AD pathology for whom information is needed to determine prognosis | 8 |
14. Patients whose eligibility for treatment with approved amyloid-targeting therapy must be determined | 9 |
15. Patients whose response must be monitored after receiving approved amyloid-targeting therapy | 8 |
Uncertain use (scores of 4–6) | |
4. Patients with subjective cognitive decline (cognitively unimpaired based on objective testing) who are considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history | 6 |
13. Patients with dementia due to clinically suspected AD pathology for whom information is needed to determine prognosis | 4 |
Rarely appropriate use (scores of 1–3) | |
1. Patients cognitively unimpaired and not considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history | 1 |
2. Patients cognitively unimpaired but considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history | 2 |
3. Patients with subjective cognitive decline (cognitively unimpaired based on objective testing) who are not considered at increased risk for AD based on age, known apolipoprotein E ɛ4 genotype, or multigenerational family history | 2 |
8. Patients with established biomarker-supported diagnosis of MCI or dementia due to AD pathology, for whom disease severity must be determined or disease progression tracked | 1 |
9. Patients with prodromal Lewy body disease or dementia with Lewy bodies | 1 |
10. Patients with MCI or dementia and recent cerebrospinal fluid biomarker results that are conclusive (whether consistent or not with underlying AD pathology) | 3 |
16. For nonmedical use (e.g., legal, insurance coverage, or employment screening) | 1 |
17. For use in lieu of genotyping, in patients who are suspected autosomal dominant mutation carriers | 1 |
Scenarios are numbered as in reference article (5). AUC are from (5).